It is very clear. And it is not about being in "my favor" (assuming you think this is some sort of contest, which it is not.)
A draft guidance or even a guidance document for AD therapeutic development does not need to be followed. A company is breaking no laws, nor, in the case of prodromal patient population, even going against the spirit of the guidance.
I don't understand why this is so hard for you. This is not cGMP guidance or Pharmacovigilance guidance.
Market Data 
Markets 
AI
